BB Biotech AG (BION.S) Quote| Reuters.com
Edition:
United States

BB Biotech AG (BION.S)

BION.S on Swiss Exchange

45.65CHF
11:19am EDT
Change (% chg)

CHF1.05 (+2.35%)
Prev Close
CHF44.60
Open
CHF44.70
Day's High
CHF45.80
Day's Low
CHF44.40
Volume
74,408
Avg. Vol
162,179
52-wk High
CHF64.90
52-wk Low
CHF38.98

BION.S

Chart for BION.S

About

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s... (more)

Overall

Beta: 1.26
Market Cap(Mil.): CHF2,642.55
Shares Outstanding(Mil.): 59.25
Dividend: 0.45
Yield (%): 6.50

Financials

  BION.S Industry Sector
P/E (TTM): -- 42.29 36.15
EPS (TTM): -16.83 -- --
ROI: -29.57 -6.23 14.31
ROE: -29.57 -5.61 15.51

BRIEF-BB Biotech Q1 net result swings to loss of CHF 1.2 billion

* Reports a net loss of 1.2 billion Swiss francs ($1.23 billion) for Q1 of 2016 compared to a net profit of 379 million Swiss francs for same period last year

Apr 22 2016

BRIEF-BB Biotech closes Q1 with after-tax loss of CHF 1.2 billion

* BB Biotech with after-tax loss in the first quarter of 2016

Apr 13 2016

BRIEF-BB Biotech Ag reports 5.4 pct passive stake in Cidara Therapeutics

* BB Biotech Ag reports 5.4 percent passive stake in Cidara Therapeutics as of March 31, 2016 - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Apr 04 2016

BRIEF-BB Biotech completes current share buyback program

* A total of 770,000 registered shares were bought back through second trading line Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 11 2016

BRIEF-BB Biotech proposes dividend of 14.50 Swiss francs per share

* Further significant increase in dividend of 25 pct to 14.50 Swiss francs per share, five-for-one share split proposed

Feb 19 2016

BRIEF-BB Biotech FY prelim profit after tax at CHF 653 mln

* FY prelim profit after tax at 653 million Swiss francs ($647.30 million) versus 1,470 million francs year ago

Jan 22 2016

BRIEF-BB Biotech FY after-tax profit down at CHF 653 mln

* Made a profit of 511 million Swiss francs ($507.30 million) in last quarter of 2015 (loss of 575 million Swiss francs in the third quarter)

Jan 13 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Wright Reports
$75.00
Provider : Reuters Investment Profile
$20.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.